DexCom, Inc. (DXCM)

127.39 +1.58 (+1.26%) 收市：04:00PM EDT

DexCom, Inc.

6340 Sequence Drive
San Diego, CA 92121
United States
858 200 0200
https://www.dexcom.com

版塊: Healthcare
行業: Medical Devices
全職員工: 9,500

高階主管

名稱	頭銜	支付	行使價	出生年份
Mr. Kevin Ronald Sayer	Executive Chairman, CEO & President	3.23M	無	1958
Mr. Jereme M. Sylvain	Executive VP, CFO & Chief Accounting Officer	1.13M	無	1980
Mr. Jacob Steven Leach	Executive VP & COO	1.29M	無	1978
Mr. Michael Jon Brown	Executive VP & Chief Legal Officer	1.22M	無	1970
Ms. Teri Lawver	Executive VP & Chief Commercial Officer	1.41M	無	1967
Mr. Girish Naganathan	Executive VP & CTO	423.92k	無	1977
Mr. Shelly Ramasamy Selvaraj	Senior VP & Chief Information Officer	無	無	1959
Mr. Sean Christensen	Director of Corporate Affairs & Head of Investor Relations	無	無	無
Mr. Matthew Dolan	Executive Vice President of Strategy, Corporate Development & Dexcom Labs	無	無	1981
Ms. Leverne Marsh	Executive Vice President of Marketing	無	無	無

截止 2023年12月31日為止計算的金額，現金賠償則計算至上一個財政年度末止。薪資是指薪俸、獎金等。已行使價是指財政年度期間已行使的期權價值。貨幣為 USD。

描述

DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions. It has also submitted FDA review for Dexcom Stelo for people with type 2 diabetes. The company has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California.

公司管治

截至 2024年4月29日 止，DexCom, Inc. 的 ISS 管治質素評分為 4。 Pillar 分數正在審核中：1；董事會：8；股東權利：6；現金賠償：2。

企業管治評分的資料提供： Institutional Shareholder Services (ISS). 評分將以 1 至 10 分顯示 (與指數或地區相關)。1 分表示較低的管治風險，而 10 分表示較高的管治風險。